Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The TELI results of DNA damage responses to
2019-09-05

The TELI results of DNA damage responses to CAA and SO then informed our choice of bacterial strains in subsequent experiments. We investigated E. coli cellular survival in response to CAA and SO exposure by determining the sensitivity of a number of E. coli strains, each possessing single or multi
-
99 8 The present review also summarizes the efforts that hav
2019-09-05

The present review also summarizes the efforts that have been made to find new c-FMS inhibitors under clinical trial as given in the Table 1. These inhibitors may reduce the burdens of potency and side effects that have faced the scientists globally. ABT-869 41 was manufactured in Abbott laboratorie
-
Furthermore we explored the effect of PKC on SIRT phosphoryl
2019-09-05

Furthermore, we explored the effect of PKCζ on SIRT6 phosphorylation. Accumulating data showed that aPKC isoforms are involved in regulating lipid metabolism [41], [42], [43], [44], [45], [46], [47]. The aPKC activity was reported to play a dominant role in normal insulin signaling by activating PI3
-
ARL 67156 trisodium salt Measurement of Chol absorption synt
2019-09-05

Measurement of Chol absorption, synthesis and catabolism would be very helpful to determine the underlying cause of hypercholesterolemia in individual patients at risk for atherosclerosis. The information could help to determine the best therapeutic approach to reduce Chol absorption, to reduce Chol
-
Measurement of Chol absorption synthesis
2019-09-05

Measurement of Chol absorption, synthesis and catabolism would be very helpful to determine the underlying cause of hypercholesterolemia in individual patients at risk for atherosclerosis. The information could help to determine the best therapeutic approach to reduce Chol absorption, to reduce Chol
-
Selective inhibitor of phosphodiesterase type PDE I is commo
2019-09-05

Selective inhibitor of phosphodiesterase type 5 (PDE5I) is commonly used for ED treatment. PDE5I exhibits its vasodilatory effect by inhibiting the degradation of cyclic guanosine monophosphate (cGMP), which relaxes the smooth muscle and allows increased blood flow for penile tumescence. Udenafil (D
-
One of the most fundamental distinctions between Ub signals
2019-09-05

One of the most fundamental distinctions between Ub signals is substrate monoubiquitination versus polyubiquitination. With the exception of the E2, UBE2W, which represents a special case because it AMG 9810 only ubiquitinates the flexible N-termini of substrates [5], [6], [20], most examples of mo
-
br Materials and Methods br Acknowledgements
2019-09-05

Materials and Methods Acknowledgements We thank the staff of beamlines ID29 and ID30A-1 of the European Synchrotron Radiation Facility. This work was supported by, the Marie Curie Career Integration Grant (PCIG13-GA-2013-630755), the Israel Science Foundation (Grant 1383/17) and the Israeli Ca
-
br Discussion br Conflicts of interest br Acknowledgment br
2019-09-05

Discussion Conflicts of interest Acknowledgment Introduction Ewing\'s sarcoma (EWS) is a bone cancer arising mostly in children. In 1921, EWS was originally described as “diffuse endothelioma of bone” by Dr. James R. Ewing, an American pathologist [1]. In 1992, Ewing sarcoma breakpoint r
-
br Enzyme catalysis A biochemically spontaneous process proc
2019-09-05

Enzyme catalysis A biochemically spontaneous process proceeds in a direction where free 7ACC1 mass of the system decreases. However, every spontaneous or energetically favorable reaction needs to overcome an energy barrier known as the activation energy barrier because of the formation of an uns
-
It is particularly notable that CYP
2019-09-05

It is particularly notable that CYP2D6 appears to be the most stable of the major CYP450 acpt in its expression over time in vitro and appears to be least affected by culture conditions and sample to sample variability (i.e., CYP2D6 expression is remarkably consistent over time and between individu
-
Fluorescein-12-dUTP Nociceptive and hyperalgesic actions of
2019-09-04

Nociceptive and hyperalgesic actions of ET-1 are produced through ETA and ETB receptors. Previous reports indicate that ETA receptor antagonists in peripheral tissues are effective in inhibiting ET-1 induced hyperalgesia, and attenuation of neuropathic pain in rats [16]. Studies have also shown that
-
br Conclusion In conclusion our findings do
2019-09-04

Conclusion In conclusion, our findings do not suggest that HT is an important determinant of future AD risk and are in line with a recent Cochrane review stating that HT is not indicated for preventing dementia or cognitive decline in postmenopausal women [13]. Contributors Conflict of inte
-
A factor that complicates the use
2019-09-04

A factor that complicates the use of human liver loxo 101 is one of variability, which arises in part because many of the human liver samples available for research show various stages of a variety of disease states (steatosis (fatty liver), cirrhosis, carcinogenesis in adjacent tissue), although c
-
Until recently the first line treatment of RLS was
2019-09-04

Until recently, the first line treatment of RLS was the administration of low dose of three dopaminergic drugs, which has been approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of moderate to severe RLS. These compounds are pramipexole (Mirapex), rop
16023 records 964/1069 page Previous Next First page 上5页 961962963964965 下5页 Last page